CDMO Blog

CCRM Collaborates To Tighten Timelines and Prepare Nkarta for IND Filing

close

Categories

See More

Subscribe to Email Updates

Popular Stories

Viral Aggregation in Downstream Processing of Lentiviral Vectors May 11, 2020
IQ, OQ and PQ: Why Are They Important in the Manufacturing of Cell and Gene Therapies? Oct 24, 2019
5 Considerations for Scaling-Up PSC-Derived Cell Therapies Mar 04, 2021
Five Steps to Ensure Your Cell and Gene Therapy Product Is GMP Compliant Oct 30, 2019
What is a Bioreactor and How is it Used in Cell and Gene Therapy? Oct 24, 2019
Categories | Subscribe | Popular
03 Aug 2021

CCRM Collaborates To Tighten Timelines and Prepare Nkarta for IND Filing

CCRM works with customers in a collaborative manner to enable them to ...

27 Jul 2021

3 Ways Your CDMO Can Help You Avoid Supply Chain Problems

The COVID-19 pandemic has significantly disrupted supply chains and pr...

11 Dec 2020

4 Tips from the Experts: How to Tighten Your Timeline from Development to Trial

Responsibly moving a cell or gene therapy forward as quickly as possib...

01 Dec 2020

3 Considerations When Developing Your LVV Program

If you are looking to get a lentiviral vector (LVV) program off the gr...

12 Aug 2020

CDMOs: The Good, the Great and the Exceptional (and How to Tell the Difference)

Outsourcing to a contract development and manufacturing organization (...

10 Jan 2020

Road to success: Understanding Good Laboratory Practice for cell and gene therapies

Good Laboratory Practice (GLP) studies are essential for generating no...

Tell us what you thought about this post.
Business people meeting around table in modern space

Subscribe to our blog.

Receive updates on the latest trends in cell & gene therapy.

Subscribe to Email Updates

© 2021 All Rights Reserved